Krsnaa diagnostics Limited has announced its quarterly earnings conference call to discuss Q3FY26 financial results. The company filed the disclosure under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, on January 30, 2026.

Conference Call Details

The earnings call is scheduled for Friday, February 6, 2026, at 12:30 PM IST. The session will begin with management discussion on results for the quarter and nine months ended December 31, 2025, followed by an interactive question and answer session.

Management Participation

Several key executives from Krsnaa Diagnostics will participate in the earnings call to discuss the company's quarterly performance:

• Mr. Rajendra Mutha - Chairman & Whole-time Director
• Mr. Yash Mutha - Managing Director
• Ms. Pallavi Bhatvara - Executive Director
• Mr. Mitesh Dave - Group CEO
• Mr. Vivek Jain - Head Investor Relations

Soorya Patra from PhillipCapital India will lead the conference call proceedings.

Access Information

Investors and analysts can join the conference call through multiple channels. The company has provided both universal dial-in numbers and toll-free options for international participants.

Dial-in Numbers

Participants can also use the DiamondPass express registration for immediate access without wait time through the provided online registration link.

Post-Call Documentation

Following the earnings conference call, Krsnaa Diagnostics will upload the complete transcript and audio recording on its official investor relations website at www.krsnaadiagnostics.com/investors . This ensures broader accessibility for stakeholders who cannot participate in the live session.

The disclosure was signed by Company Secretary and Compliance Officer Sujoy Sudipta Bose, with the company maintaining its commitment to transparency and regulatory compliance under SEBI guidelines.

Krsnaa Diagnostics has announced the resignation of its Chief Financial Officer, Mr. Pawan Daga, effective January 19, 2026. The healthcare diagnostics company informed stock exchanges about this key managerial personnel change through a regulatory filing on January 15, 2026.

Resignation Details

The company filed the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. According to the filing, Daga's last working day will be until the close of business hours on January 19, 2026.

Management's Acknowledgment

The management has placed on record its sincere appreciation for Daga's services during his five-year tenure with Krsnaa Diagnostics. The company specifically acknowledged his contribution to the organization's growth during this period.

In his resignation letter dated January 15, 2026, Daga expressed gratitude for the trust, opportunities, and support extended by the Board and management team. He highlighted his experience working with the finance function and various financial and strategic initiatives aimed at strengthening the company's financial health and governance framework.

Regulatory Compliance

The disclosure was made in compliance with multiple SEBI regulations and circulars, including:

• Regulation 30(6) read with clause 7C of Para A of Part A of schedule III of the SEBI Listing Regulations
• SEBI Circular No SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
• SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024

The filing was signed by Sujoy Sudipta Bose, Company Secretary and Compliance Officer of Krsnaa Diagnostics Limited. The company has confirmed that there are no other reasons beyond personal and professional priorities for the CFO's resignation.

About the Departure

Daga confirmed in his resignation letter that the decision was made after careful consideration of his personal and professional priorities. He expressed confidence that the finance function is well-positioned for continued success and conveyed his thanks to the Board, senior management team, and colleagues for the enriching experience.